Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for  months after the last drug administration
Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control while being treated on this study
Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study
STRATUM A: Male participants of child fathering potential must be willing to use medically acceptable form of contraception during treatment and for  weeks after stopping treatment
STRATUM B: Male participants of child fathering potential must be willing to use medically acceptable form of contraception during treatment and for  weeks after stopping treatment
STRATUM C: Male participants of child fathering potential must be willing to use medically acceptable form of contraception during treatment and for  months after stopping treatment
Female patients of childbearing potential must have negative serum or urine pregnancy test within  hours of the first dose of MEK; patient must not be pregnant or breast-feeding; patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for  days following cessation of treatment
Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study
Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence during study treatment and  months after the last dose of alisertib
Males must agree to use a medically acceptable form of birth control in order to be in this study and for  months after infusion
Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study
Females of childbearing age must be on an acceptable form of birth control per institutional standards
Males who cannot comply with birth control use to avoid fathering a child
Fertile male patients willing to use at least one medically acceptable form of birth control for the duration of the study and for  weeks after treatment stops.
Subjects of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study
Subjects of childbearing potential requires acceptable form of birth control
Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study
Fertile male subjects willing to use at least one medically acceptable form of birth control for the duration of the study and for  weeks after treatment stops
Non-menopausal or non-sterile female subjects of childbearing potential must have a negative serum beta-HCG and use a medically acceptable form of birth control
RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for  months after the last dose of panobinostat
NON-PROGRESSED DIPG (STRATUM ): Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for  months after the last dose of panobinostat
Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study
Subjects of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study (cohort )
Subjects of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study
All patients of childbearing age must use an acceptable form of birth control
All patients of childbearing and child-creating age must be using an acceptable form of birth control
All patients of childbearing and child-creating age must be using an acceptable form of birth control
Pregnancy, lactation or inability to use medically acceptable birth control if of childbearing potential
